Not Signed In -
Mitotane |
Lysodren |
Article: Mitotane
| Image:Mitotane.png | |
| Mitotane | |
| Systematic (IUPAC) name | |
| 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)-ethyl]-benzene | |
| Identifiers | |
| CAS number | 53-19-0 |
| ATC code | L01XX23 |
| PubChem | 4211 |
| DrugBank | APRD00494 |
| Chemical data | |
| Formula | C14H10Cl4 |
| Mol. weight | 320.04 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 6% |
| Metabolism | ? |
| Half life | 18-159 days |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | |
| Routes | ? |
Mitotane is a substance used for the rare disease adrenocortical carcinoma.
It has been produced by Bristol Myers Squibb SpA but it is marketed as an orphan drug due to the small number of patients in need of it. Its administration occurs in cases where the tumour cannot be surgically omitted.
Mitotane alternates steroides peripheral metabolism, represses directly the adrenal cortex and alternates cortisone metabolism. It is an isomere chemically to DDT.
Its trade name is LYSODREN.
email this page
print this page
bookmark this page
feedback on this page
